Table 4.
Summary of QTcB (milliseconds) during the study period
| 2-DG 63 mg + SOC | SOC1 | 2-DG 90 mg + SOC | 2-DG 126 mg + SOC | SOC2 | ||
|---|---|---|---|---|---|---|
| Baseline | N | 22 | 21 | 22 | 21 | 18 |
| Mean (SD) | 407.0 (32.79) | 412.5 (29.45) | 429.0 (27.15) | 428.6 (21.21) | 418.9 (33.06) | |
| Median | 409.5 | 413.0 | 430.0 | 423.0 | 431.5 | |
| Day 3 | N | 22 | 22 | 20 | 21 | 21 |
| Mean (SD) | 419.1 (24.46) | 412.5 (24.19) | 425.7 (32.72) | 427.5 (29.36) | 427.0 (22.31) | |
| Median | 413.0 | 406.5 | 423.0 | 427.0 | 421.0 | |
| Day 7 | N | 19 | 19 | 10 | 15 | 12 |
| Mean (SD) | 415.7 (21.86) | 412.0 (31.39) | 433.5 (30.25) | 446.7 (61.33) | 411.8 (28.40) | |
| Median | 422.0 | 408.0 | 423.0 | 444.0 | 411.5 | |
| End of Treatment | N | 22 | 22 | 19 | 21 | 19 |
| Mean (SD) | 413.1 (24.69) | 410.4 (20.61) | 433.9 (37.82) | 435.2 (36.59) | 422.4 (23.20) | |
| Median | 417.0 | 411.0 | 423.0 | 440.0 | 422.0 | |
2-DG 2-deoxy-d-glucose, SOC standard of care, SOC1 SOC in Part A of the study, SOC2 SOC in Part B of the study